← Back to patent-cliff list
CAS 75-03-6
1-Iodoethane
Codes: (VIII)819703-2-a, (II)638294-3-a, (VII)638294-14-a, (III)115092-6-a, (III)115092-8-a, Atosiban-054, Mosapride Citrate-002, (XII)989842-1-b
Application context (from source-drug indications)
Gastrointestinal stromal tumourRipretinibSystolic heart failureFinerenoneDiastolic heart failureFinerenoneHeart failureFinerenoneChronic renal impairmentFinerenoneDiabetic nephropathyFinerenoneType 2 diabetesFinerenoneGlaucomaProxodolol hydrochloride/Pilocarpine Hydrochloride闭角型青光眼Pilocarpine HydrochlorideOcular hypertensionPilocarpine HydrochlorideOpen-angle glaucomaPilocarpine Hydrochloride瞳孔缩小Pilocarpine HydrochlorideSjögren's syndromePilocarpine Hydrochloride虹膜炎Pilocarpine Hydrochloride产科分娩（早产）Atosiban acetate早产（孕37周前）Atosiban acetateEndometriosisAtosiban acetateGastritisMosapride CitrateEnteral feeding intoleranceMosapride CitrateIrritable bowel syndromeMosapride CitrateDyspepsiaMosapride CitrateConstipationMosapride CitratePlaque psoriasisMufemilastUlcerative colitisMufemilastBehçet's syndromeMufemilastPsoriasisMufemilastChronic obstructive pulmonary diseaseMufemilastAtopic dermatitisMufemilast
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ripretinib | Tier C — Watch / trade | 2032 |
| Finerenone | Tier C — Watch / trade | 2030 |
| Proxodolol hydrochloride/Pilocarpine Hydrochloride | Tier C — Watch / trade | - |
| Pilocarpine Hydrochloride | Tier C — Watch / trade | - |
| Atosiban acetate | Tier C — Watch / trade | - |
| Mosapride Citrate | Tier C — Watch / trade | - |
| Mufemilast | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
Methyl (2-bromo-4-fluoro-5-nitrophenyl)acetate→6-Chloro-4-nitropyridine-3-carbaldehyde→Methyl (2Z)-2-(2-bromo-4-fluoro-5-nitrophenyl)-3-(6-chloro-4-nitropyridin-3-yl)prop-2-enoate→3-(5-Amino-2-bromo-4-fluorophenyl)-7-chloro-1,6-naphthyridin-2(1H)-one→Aminobenzene→1,1,1-Trichloromethanol 1,1'-carbonate→N-[4-Bromo-5-(7-chloro-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl]-N'-phenylurea→1-Iodoethane→N-[4-Bromo-5-(7-chloro-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl]-N'-phenylurea→Aminomethane
4-Amino-5-methylpyridin-2(1H)-one→1-Iodoethane→2-Ethoxy-5-methylpyridin-4-amine→N-(2-Ethoxy-5-methylpyridin-4-yl)-2,2-dimethylpropanamide→2-Methoxy-4-cyanobenzaldehyde→N-[3-[(4-Cyano-2-methoxyphenyl)(hydroxy)methyl]-2-ethoxy-5-methylpyridin-4-yl]-2,2-dimethylpropanamide→4-[(4-Amino-2-ethoxy-5-methylpyridin-3-yl)(hydroxy)methyl]-3-methoxybenzonitrile→3-Oxobutanamide→(±)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide→4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,6-naphthyridine-3-carboxamide→(aS)-10,16-Di(anthracen-9-yl)-13-hydroxy-12,14-dioxa-13lambda5-phosphapentacyclo[13.8.0.02,11.03,8.018,23]tricosa-1(15),2(11),3,5,7,9,16,18,20,22-decaene 13-oxide
4-Bromo-2-methoxybenzaldehyde→3-Oxobutanamide→(2Z)-2-[(4-Bromo-2-methoxyphenyl)methylidene]-3-oxobutanamide→4-Amino-5-methylpyridin-2(1H)-one→4-(4-Bromo-2-methoxyphenyl)-2,5-dihydroxy-2,8-dimethyl-1,2,3,4-tetrahydro-1,6-naphthyridine-3-carboxamide→4-(4-Bromo-2-methoxyphenyl)-5-hydroxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide→1-Iodoethane→4-(4-Bromo-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide→(4S)-4-(4-Bromo-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
(2R)-2-Hydroxysuccinic acid→(R)-2-Hydroxysuccinic acid dimethylester→1-Iodoethane→Diethyl (2S,3R)-2-methyl-3-hydroxysuccinate→Dimethyl (2S,3R)-2-ethyl-3-[(4-nitrobenzene-1-sulfonyl)oxy]butanedioate→Dimethyl (3R)-2-bromo-3-ethylbutanedioate→1-Methyl-1H-imidazole-5-carbaldehyde→Methyl (3S,4S)-4-ethyl-2-(1-methyl-1H-imidazol-5-yl)-5-oxooxolane-3-carboxylate→(2S,3R)-2-Ethyl-4-methoxy-3-[(1-methyl-1H-imidazol-5-yl)methyl]-4-oxobutanoic acid
(2R)-2-Hydroxysuccinic acid→(R)-Diethyl malate→(R)-Diisopropyl 2-hydroxysuccinate→1-Iodoethane→Diethyl (2S,3R)-2-ethyl-3-hydroxybutanedioate→Dipropan-2-yl (2S,3R)-2-ethyl-3-hydroxybutanedioate→Diethyl (2S,3R)-2-ethyl-3-[(4-nitrobenzene-1-sulfonyl)oxy]butanedioate→Dipropan-2-yl (2S,3R)-2-ethyl-3-[(4-nitrobenzene-1-sulfonyl)oxy]butanedioate→Diethyl (3R)-2-bromo-3-ethylbutanedioate→Diisopropyl 2-bromo-3(R)-ethyl-butanedioate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | 4-Bromo-2-methoxybenzaldehyde Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 4-formyl-3-methoxybenzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 4-AMino-5-Methylpyridin-2-ol Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-chloro-5-methylpyridin-4-amine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Cyanoethyl 3-oxobutanoate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.